Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02284919 · ClinicalTrials.gov registry record · Phase 1

[18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer

A Phase 1 study of Breast Cancer and Breast Neoplasm, sponsored by University of Pennsylvania.

Active
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT02284919: Active Phase 1 study of Breast Cancer and Breast Neoplasm, sponsored by University of Pennsylvania.

NCT02284919 is a Phase 1 study of Breast Cancer and Breast Neoplasm that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 30 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02284919, a Phase 1 study of Breast Cancer and Breast Neoplasm, is active but no longer recruiting, sponsored by University of Pennsylvania.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

In this study, positron emission tomography (PET/CT) imaging will be used to evaluate sigma-2 (σ2) receptor activity in sites of primary breast cancer using the investigational radiotracer \[18F\]ISO-1.

Primary Outcome

Correlate \[18F\]ISO-1 uptake with pathologic assays measuring cellular proliferation rates (e.g. Ki-67)

Conditions Studied

Breast Cancer Breast Neoplasm

Interventions

  • DRUG [18F]ISO-1

Study Locations (1)

Pennsylvania

  • University of Pennsylvania Hospital - Philadelphia

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2015-03-11
Est. Completion 2026-11
Phase Phase 1
University of Pennsylvania

1,423 total trials

What the registry record for NCT02284919 still lists

NCT02284919 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which [18F]ISO-1 is the first listed.

NCT02284919 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02284919 about?

NCT02284919 is a clinical study titled "[18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer". In this study, positron emission tomography (PET/CT) imaging will be used to evaluate sigma-2 (σ2) receptor activity in sites of primary breast cancer using the investigational radiotracer \[18F\]ISO-1.

What is the current status of trial NCT02284919?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2015-03-11. Estimated completion is 2026-11.

What conditions does trial NCT02284919 study?

This clinical trial studies the following conditions: Breast Cancer, Breast Neoplasm.

What interventions are being tested in trial NCT02284919?

The interventions under investigation include: [18F]ISO-1 (DRUG).

Who is sponsoring clinical trial NCT02284919?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02284919 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02284919's enrollment target sits among peer trials

30 955th of 1224 higher than 227 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02284919, the US trial registry maintained by the National Library of Medicine. NCT02284919 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.